Wedbush Estimates Nuvation Bio’s FY2025 Earnings (NYSE:NUVB)

Nuvation Bio Inc. (NYSE:NUVB) – Analysts at Wedbush upped their FY2025 earnings estimates for shares of Nuvation Bio in a report issued on Tuesday, November 4th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.57) for the year, up from their previous forecast of ($0.68). Wedbush has a “Outperform” rating and a $6.00 price objective on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Nuvation Bio’s Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.23) EPS and FY2028 earnings at $0.03 EPS.

A number of other research firms also recently commented on NUVB. Citizens Jmp raised their price objective on shares of Nuvation Bio from $6.00 to $8.00 and gave the stock a “market outperform” rating in a report on Tuesday. Royal Bank Of Canada raised their price objective on shares of Nuvation Bio from $7.00 to $8.00 and gave the stock an “outperform” rating in a report on Tuesday. Jefferies Financial Group started coverage on shares of Nuvation Bio in a report on Tuesday, September 30th. They set a “buy” rating and a $10.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Nuvation Bio in a report on Friday, September 19th. Finally, Citigroup reissued a “market outperform” rating on shares of Nuvation Bio in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.57.

Nuvation Bio Stock Performance

NYSE NUVB opened at $4.91 on Thursday. The company’s fifty day moving average is $3.75 and its two-hundred day moving average is $2.79. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -7.67 and a beta of 1.50. Nuvation Bio has a 52-week low of $1.54 and a 52-week high of $5.55. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.48 and a quick ratio of 9.38.

Nuvation Bio (NYSE:NUVB) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. The company had revenue of $13.12 million for the quarter, compared to analyst estimates of $7.48 million. Nuvation Bio had a negative net margin of 813.07% and a negative return on equity of 54.99%.

Institutional Investors Weigh In On Nuvation Bio

Several institutional investors have recently modified their holdings of the business. LCM Capital Management Inc grew its position in shares of Nuvation Bio by 29.2% during the 3rd quarter. LCM Capital Management Inc now owns 15,500 shares of the company’s stock worth $57,000 after buying an additional 3,500 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Nuvation Bio by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,547 shares of the company’s stock valued at $191,000 after purchasing an additional 4,608 shares during the period. Meridian Wealth Management LLC grew its holdings in Nuvation Bio by 5.8% during the second quarter. Meridian Wealth Management LLC now owns 87,115 shares of the company’s stock valued at $170,000 after purchasing an additional 4,780 shares during the period. Cresset Asset Management LLC grew its holdings in Nuvation Bio by 3.5% during the second quarter. Cresset Asset Management LLC now owns 143,690 shares of the company’s stock valued at $280,000 after purchasing an additional 4,874 shares during the period. Finally, Federated Hermes Inc. grew its holdings in Nuvation Bio by 75.9% during the third quarter. Federated Hermes Inc. now owns 11,630 shares of the company’s stock valued at $43,000 after purchasing an additional 5,020 shares during the period. Institutional investors and hedge funds own 61.67% of the company’s stock.

Insider Activity at Nuvation Bio

In other news, insider Gary Hattersley sold 100,000 shares of Nuvation Bio stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $5.02, for a total transaction of $502,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 29.93% of the stock is currently owned by corporate insiders.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.